Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FB-102 by Forte Biosciences for Alopecia Areata: Likelihood of Approval
FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Alopecia Areata. According to GlobalData, Phase...
FB-102 by Forte Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval
FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Graft Versus Host Disease (GVHD). According...
FB-102 by Forte Biosciences for Vitiligo: Likelihood of Approval
FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Vitiligo. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Forte Biosciences's FB-102?
FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Graft Versus Host Disease...